199 related articles for article (PubMed ID: 33116571)
1. Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety.
Ni J; Cheng X; Chen J; Guo W; Dai Z
Onco Targets Ther; 2020; 13():9857-9863. PubMed ID: 33116571
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of mono-anlotinib mono therapy or in combination with chemotherapy in platinum-resistant recurrent ovarian cancer: a single-center retrospective study.
Wu Y; Li P; Zhu Y; Zhang F; Su L; Ye Y; Huang Y; Zhang M
Am J Transl Res; 2023; 15(3):1973-1981. PubMed ID: 37056822
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
Cui Q; Hu Y; Ma D; Liu H
Drug Des Devel Ther; 2021; 15():339-347. PubMed ID: 33536747
[TBL] [Abstract][Full Text] [Related]
4. Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma.
She L; Su L; Shen L; Liu C
Front Oncol; 2021; 11():687564. PubMed ID: 34354945
[TBL] [Abstract][Full Text] [Related]
5. A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study.
Liu G; Feng Y; Li J; Deng T; Yin A; Yan L; Zheng M; Xiong Y; Li J; Huang Y; Zhang C; Huang H; Wan T; Huang Q; Lin A; Jiang J; Kong B; Liu J
EClinicalMedicine; 2022 Dec; 54():101767. PubMed ID: 36583171
[TBL] [Abstract][Full Text] [Related]
6. A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer.
Wang HY; Chu JF; Zhao Y; Tang H; Wang LL; Zhou MQ; Yan Z; Liu YY; Yao ZH
Cancer Manag Res; 2020; 12():3827-3834. PubMed ID: 32547218
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.
Yin J; Yin W; Zheng L; Li Y; Luo C; Zhang S; Duan L; Zhou H; Cheng K; Lang J; Xu K
Clin Med Insights Oncol; 2023; 17():11795549231175714. PubMed ID: 37435019
[TBL] [Abstract][Full Text] [Related]
8. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
[TBL] [Abstract][Full Text] [Related]
9. A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma.
Li Q; Su T; Zhang X; Pan Y; Ma S; Zhang L; Zhang X; Gao X
Cancer Manag Res; 2022; 14():3037-3046. PubMed ID: 36275784
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study.
Jiang HT; Li W; Zhang B; Gong Q; Qie HL
Int J Gen Med; 2021; 14():7625-7637. PubMed ID: 34754233
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab.
Jiang F; Li J; Kong X; Sun P; Qu H
Front Pharmacol; 2022; 13():973448. PubMed ID: 36238567
[No Abstract] [Full Text] [Related]
12. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer.
Shao Y; Luo Z; Yu Y; He Y; Liu C; Chen Q; Zhu F; Nie B; Liu H
Front Oncol; 2022; 12():939343. PubMed ID: 35965587
[TBL] [Abstract][Full Text] [Related]
13. Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.
Nie C; He Y; Lv H; Gao M; Gao X; Chen B; Xu W; Wang J; Liu Y; Zhao J; Chen X
Front Oncol; 2022; 12():885350. PubMed ID: 35860585
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.
Wang HY; Chu JF; Zhang P; Wang JQ; Yan Z; Yao SN; Yao ZH; Liu YY
Onco Targets Ther; 2020; 13():1561-1568. PubMed ID: 32110053
[TBL] [Abstract][Full Text] [Related]
15. Combined use of Anlotinib with chemotherapy in patients with advanced ovarian cancer: a real-world cohort study and meta-analysis.
Hong X; Qiu S; Ding B; Xu H; Shen Y
Ther Adv Med Oncol; 2024; 16():17588359231221336. PubMed ID: 38188470
[TBL] [Abstract][Full Text] [Related]
16. Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study.
Shen W; Jing C; Tian W; Zhang W; Ren Y; Shan B; Wang H
Int J Gynecol Cancer; 2023 Nov; 33(11):1764-1770. PubMed ID: 37775281
[TBL] [Abstract][Full Text] [Related]
17. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
Liu J; Deng YT; Jiang Y
Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study.
Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Ruan ZP; Tian T; Liang X; Yao Y
Front Oncol; 2022; 12():894835. PubMed ID: 36203439
[TBL] [Abstract][Full Text] [Related]
19. Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study.
Yuan M; Zhu Z; Mao W; Wang H; Qian H; Wu J; Guo X; Xu Q
Front Oncol; 2021; 11():683502. PubMed ID: 34692475
[TBL] [Abstract][Full Text] [Related]
20. Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study.
Zou H; Xia L; Jin G; Wu H; Qian W; Jia D; Xu H; Li T
Cancer Manag Res; 2022; 14():1703-1711. PubMed ID: 35585940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]